Drug Profile
PEG(E)-TC 11
Alternative Names: PEG(E)-TC11Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator IDAC Theranostics; Keio University; Saitama University
- Class Antineoplastics; Phthalimides
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Nucleophosmin inhibitors; Osteoclast inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in Japan
- 01 Apr 2017 Preclinical trials in Cancer in Japan (unspecified route) before April 2017
- 01 Apr 2017 Preclinical data in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)